|
|
|
|
Lobbying mounts to get Florida approval of two costly schizophrenia drugs
When the public pays the bill, who decides whether a pricey new drug is worth the cost?For Florida's Medicaid patients, those recommendations come from a panel of doctors and pharmacists who review medications to determine if they should be on the state's...
|
|
|
Lobbying effort mounts to get costly schizophrenia drugs approved
When the public pays the bill, who decides whether a pricey new drug is worth the cost?For Florida's Medicaid patients, those recommendations come from a panel of doctors and pharmacists who review medications to determine if they should be on the state's...
|
|
|
Lawsuits filed over drug side effects
A Philadelphia law firm yesterday said it filed 10 lawsuits on behalf of boys and young men who developed serious side effects -- including the growth of breasts -- while taking the antipsychotic medications Risperdal and Invega.The suits were filed in...
|
|
|
Lilly's Effient: Cheap Enough, for Now
Eli Lilly (NYSE: LLY) is late to the party, but it's getting gussied up anyway in the hopes of attracting at least a few new friends before the party winds down.The company's blood thinner, Effient, was approved by the Food and Drug Administration last July....
|
|
|
Lilly's Effient: Cheap Enough, for Now
Eli Lilly (NYSE: LLY) is late to the party, but it's getting gussied up anyway in the hopes of attracting at least a few new friends before the party winds down.The company's blood thinner, Effient, was approved by the Food and Drug Administration last July....
|
|
|
Lilly's Effient: Cheap Enough, for Now
Eli Lilly (NYSE: LLY) is late to the party, but it's getting gussied up anyway in the hopes of attracting at least a few new friends before the party winds down.The company's blood thinner, Effient, was approved by the Food and Drug Administration last July....
|
|
|
Study shows Invega efficient in lowering metabolic effects compared to olanzapine
New data from a six-month open label randomised controlled trial show Invega (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.The...
|
|
|
Commercial Insight: Antipsychotics - Revenues Of Depots And New Agents Will Partially Offset Generic Erosion -
New report provides detailed analysis of the Healthcare and Medical market Published on November 19, 2009by Press Office(Companiesandmarkets.com and OfficialWire)LONDON, ENGLAND In 2008, seven major market sales of antipsychotics reached $18.2 billion.
|
